MARCHI, SANTINO
 Distribuzione geografica
Continente #
NA - Nord America 17.620
EU - Europa 8.715
AS - Asia 2.963
AF - Africa 240
SA - Sud America 49
OC - Oceania 47
Continente sconosciuto - Info sul continente non disponibili 8
Totale 29.642
Nazione #
US - Stati Uniti d'America 17.071
IT - Italia 3.508
CN - Cina 1.602
SE - Svezia 1.443
BG - Bulgaria 861
UA - Ucraina 667
DE - Germania 658
CA - Canada 539
SG - Singapore 489
GB - Regno Unito 464
VN - Vietnam 386
FI - Finlandia 330
CH - Svizzera 299
TR - Turchia 252
CI - Costa d'Avorio 130
AT - Austria 110
RU - Federazione Russa 100
HK - Hong Kong 93
FR - Francia 87
IN - India 66
BE - Belgio 47
NG - Nigeria 42
AU - Australia 39
SN - Senegal 36
NL - Olanda 30
PL - Polonia 21
ES - Italia 19
BJ - Benin 16
EC - Ecuador 13
KR - Corea 13
NO - Norvegia 13
HU - Ungheria 12
JP - Giappone 12
BR - Brasile 10
EG - Egitto 10
MX - Messico 10
CL - Cile 9
CZ - Repubblica Ceca 8
GR - Grecia 8
IR - Iran 8
NZ - Nuova Zelanda 8
AR - Argentina 7
CO - Colombia 7
EU - Europa 7
ID - Indonesia 7
IE - Irlanda 7
IL - Israele 7
DK - Danimarca 6
RS - Serbia 5
TW - Taiwan 5
AE - Emirati Arabi Uniti 4
MY - Malesia 3
PE - Perù 3
PH - Filippine 3
PK - Pakistan 3
BN - Brunei Darussalam 2
DZ - Algeria 2
ET - Etiopia 2
KZ - Kazakistan 2
RO - Romania 2
SA - Arabia Saudita 2
SK - Slovacchia (Repubblica Slovacca) 2
A1 - Anonimo 1
AL - Albania 1
AZ - Azerbaigian 1
EE - Estonia 1
HR - Croazia 1
KG - Kirghizistan 1
LK - Sri Lanka 1
LT - Lituania 1
LU - Lussemburgo 1
LV - Lettonia 1
MA - Marocco 1
ME - Montenegro 1
SC - Seychelles 1
SI - Slovenia 1
TH - Thailandia 1
Totale 29.642
Città #
Woodbridge 2.314
Ann Arbor 2.130
Houston 1.660
Chandler 1.483
Fairfield 1.368
Serra 1.183
Jacksonville 918
Milan 879
Sofia 861
Ashburn 770
Seattle 602
Beijing 582
Wilmington 521
New York 512
Cambridge 511
Ottawa 509
Princeton 377
Boardman 370
Lawrence 341
Nanjing 333
Medford 314
Bern 293
Des Moines 265
Izmir 244
Dearborn 192
Singapore 179
Jüchen 168
Dong Ket 153
Nanchang 131
Abidjan 130
London 118
Boulder 111
Vienna 103
Redwood City 96
Florence 86
Hong Kong 83
Kunming 83
San Diego 82
Pisa 64
Hebei 58
Changsha 54
Rome 53
Shenyang 53
Tianjin 53
Brussels 44
Lagos 42
Washington 42
Ogden 40
Dakar 36
Hefei 33
Falls Church 32
Jiaxing 32
Bremen 31
Norwalk 31
Verona 30
Los Angeles 28
Orange 28
Pune 25
Lancaster 24
Lanzhou 22
Auburn Hills 21
Kent 21
Phoenix 21
Guangzhou 20
Livorno 19
Jinan 18
Frankfurt am Main 17
Cotonou 16
Hangzhou 16
Lucca 15
Shanghai 15
Toronto 15
Dallas 14
Redmond 14
Amsterdam 13
Council Bluffs 13
Massa 13
Alessandria 12
Chicago 12
San Francisco 12
Southend 11
Sydney 11
Changchun 10
Groningen 10
Nürnberg 10
Chengdu 9
Düsseldorf 9
Pécs 9
Bergen 8
Empoli 8
Helsinki 8
Melbourne 8
Warsaw 8
Cairo 7
Hyderabad 7
Indiana 7
Xian 7
Detroit 6
Dublin 6
Fuzhou 6
Totale 22.392
Nome #
Evaluation of Pancreatic Exocrine Function in Patients With Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas 288
Serum gamma-glutamyltransferase fractions in myotonic dystrophy type I: differences with healthy subjects and patients with liver disease 217
Management of Chronic constipation in general practice 179
Symptom analysis improves GERD diagnosis and may be helpful to define a successful surgical approach 164
Differential diagnosis between functional and organic intestinal disorders: is there a role for non-invasive tests? 162
Symptom patterns can distinguish diverticular disease from irritable bowel syndrome. 161
Helicobacter pylori eradication: a randomized prospective study of triple therapy versus triple therapy plus lactoferrin and probiotics 156
Randomised clinical trial: twice daily esomeprazole 40 mg vs. pantoprazole 40 mg in Barrett’s oesophagus for 1 year 156
Neuroendocrine Dysregulation in Irritable Bowel Syndrome Patients: A Pilot Study 156
Esophageal chemical clearance and baseline impedance values in patients with chronic autoimmune atrophic gastritis and gastro-esophageal reflux disease 152
Lactobacillus Casei DG® in Patients with Irritable Bowel Syndrome: Not Only a Change of the Gut Microbiota. A Pilot Study 146
Gastroesophageal reflux symptoms among Italian university students: Epidemiology and dietary correlates using automatically recorded transactions 143
Role of faecal calprotectin as non-invasive marker of intestinal inflammation 141
Gastric mucosal distribution and clinical efficacy of azithromycin in patients with Helicobacter pylori related gastritis 141
Parallel increase of circulating CXCL11 and CXCL10 in mixed cryoglobulinemia, while the proinflammatory cytokine IL-6 is associated with high serum Th2 chemokine CCL2. 141
Not all anti-reflux treatment failures are due to persistence of abnormal esophageal acid exposure 140
Clinical features of symptomatic uncomplicated diverticular disease: a multicenter Italian survey. 140
Influence of the serotonin transporter 5HTTLPR polymorphism on symptom severity in irritable bowel syndrome 139
The general practitioner's approach to irritable bowel syndrome: from intention to practice 138
Abdominal ultrasound scan for the follow-up of pancreatic cystic lesions: could it play a role as a safe and cost-saving alternative to the routine MRI? 138
Platelet serotonin transporter in patients with diarrhea-predominant irritable bowel syndrome both before and after treatment with alosetron 136
Intestinal pseudo-obstruction in inactive systemic lupus erythematosus: An unusual finding 136
Radionuclide evaluation of the lower gastrointestinal tract 135
Management of chronic constipation in general practice. 134
Overlap of functional heartburn and gastroesophageal reflux disease with irritable bowel syndrome 133
Thrombocytopenic purpura: an unusual complication of eradication therapy for Helicobacter pylori 132
Hepatitis C virus chronic infection as a common cause of mixed cryoglobulinaemia and autoimmune liver disease 130
Dynamic MRI of the small bowel: usefulness of quantitative contrast-enhancement parameters and time-signal intensity curves for differentiating between active and inactive Crohn's disease. 130
Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they? 127
CT colonography: Project of High National Interest No. 2005062137 of the Italian Ministry of Education, University and Research (MIUR) RID A-2343-2011 126
Famotidine in the short-term treatment of duodenal ulcer and of concomitant peptic lesions : comparison with cimetidina 125
Alginate controls heartburn in patients with erosive and nonerosive reflux disease. 125
Irritable bowel syndrome: a disease still searching for pathogenesis, diagnosis and therapy 123
Role of HCV infection in immune response to hepatitis B vaccination in chronic renal failure patients on hemodialysis. 123
Barrett's esophagus results of a multicentric survey 122
Suspected laryngopharyngeal reflux evaluated with multichannel impedance and Ph-monitoring. How many are gerd patients? 122
The daily diary and the questionnaire are not equivalent for the evaluation of bowel habits 121
Thyroid involvement in hepatitis C - Associated mixed cryoglobulinemia 121
Genetics and pharmacogenetics of aminergic transmitter pathways in functional gastrointestinal disorders 120
Can interferon-ribavirin effectively treat patients who did not respond to a first conventional therapy by interferon? 119
Giant cell arteritis of the leg in a patient with hepatitis C virus infection 119
Could double-dose PPI therapy modify tissutal homeostasis in patients with barrett esophagus? 119
Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance open-label, low-dose therapy with rabeprazole 119
Subthreshold psychiatric psychopathology in Functional gastrointestinal disorders: Can it be the bridge between gastroenterology and psychiatry? 118
Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease 116
Endoscopic ND:YAG laser therapy for villous adenomas of the right colon 116
Voluntary and controlled weight loss can reduce symptoms and proton pump inhibitor use and dosage in patients with gastroesophageal reflux disease: A comparative study 116
Association between baseline impedance values and response proton pump inhibitors in patients with heartburn 116
CAGA STATUS DOES NOT INFLUENCE THE ERADICATION RATE OF HELICOBACTER PYLORI INFECTION BY A ONE WEEK TRIPLE THERAPY 115
Long-term endoscopic surveillance of patients with Barrett’s esophagus. Incidence of dysplasia and adenocarcinoma: a prospective study 115
The pharmacokinetics of ilaprazole for gastro-esophageal reflux treatment 115
Assessment of serum cytokines predicts clinical and endoscopic outcomes to vedolizumab in ulcerative colitis patients 115
Can interferon-ribavirin effectively treat patients who did not respond to a first conventional therapy by interferon? 114
Accuracy of b-GGT fraction for the diagnosis of non-alcoholic fatty liver disease 114
Retrospective, observational, multicentre study on an Italian population affected by chronic hepatitis C who failed to clear HCV-RNA after the combined therapy (PEG-IFN and ribavirin): NADIR study 114
Alfa-fetoproteina e dimero-D nell'epatocarcinoma e nelle epatopatie croniche 113
Gastroesophageal reflux disease, functional dyspepsia and irritable bowel syndrome: Common overlapping gastrointestinal disorders 113
Exploring the genetics of irritable bowel syndrome: A GWA study in the general population and replication in multinational case-control cohorts 112
How many cases of laryngopharyngeal reflux suspected by laryngoscopy are gastroesophageal reflux disease-related? 112
STUDIO DEGLI ACIDI BILIARI IN PAZIENTI CON COLESTASI E DRENAGGIO BILIARE PERCUTANEO ED IN PAZIENTI CON EPATOPATIA CRONICA NON COLESTATICA 111
Consideration concerning the psyco-medical-social approach to alcohol-related problems. 111
White Paper of Italian Gastroenterology: Delivery of services for digestive diseases in Italy: Weaknesses and strengths 111
COMMENT ON LETTER TO EDITOR 110
Assessment of the anti-reflux properties and therapeutic efficacy of Faringel in patients with mild to moderate GERD. 110
Patients with lactose intolerance absorb liquid levothyroxine better than tablet levothyroxine 110
Endoscopic features of Barrett's esophagus 109
Manually calculated oesophageal bolus clearance time increases in parallel with reflux severity at impedance-pH monitoring 109
A seven day regimen with ranitidine bismuth citrate plus amoxycillin and clarithromycin is effective in eradicating H.Pylori and healing duodenal ulcer. 108
CagA status does not influence the eradication rate of Helicobacter pylori infection by a one-week triple therapy. 108
Progressive multifocal leukoencephalopathy in autoimmune disorders 108
“PancPro” as a tool for selecting families eligible for pancreatic cancer screening: An Italian study of incident cases 108
Neuroendocrine markers and psychological features in patients with irritable bowel syndrome 108
Bimodal rehabilitation has a long lasting efficacy in pelvic floor dyssynergia. 107
Pros and Cons of the SeHCAT Test in Bile Acid Diarrhea: A More Appropriate Use of an Old Nuclear Medicine Technique 107
Liver triglyceride accumulation after chronic ethanol administration: a possible protective role of metadoxina and ubiquinon 106
Association of chronic autoimmune active hepatitis and celiac disease: a case report. 106
Diagnostic accuracy of a saliva assay for antibodies to Helicobacter pylori in dyspeptic patients referred to first upper digestive endoscopy. 106
Esophageal testing: What we have so far 106
Barrett's esophagus in 2016: From pathophysiology to treatment 106
Alcohol and women: a study in high schools 105
Chronic active hepatitis (CAH) due to hepatitis C virus (HCV): a double-blind, randomized trial of IFN ± colchicine. 104
Circulating CXCL11 and CXCL10 are increased in hepatitis C-associated cryoglobulinemia in the presence of autoimmune thyroiditis 104
Gastric emptying in myotonic dystrophic patients. 104
Double-blind, randomized trial of IFN±colchicine in anti HCV-positive chronic active Hepatitis (CAH). 103
Nuclear translocation of GSTO is a progression marker in Barrett’s esophagus. 103
Irritable bowel syndrome and chronic constipation: Fact and fiction 103
Esophageal motility abnormalities in gastroesophageal reflux disease 103
Lower pH values of weakly acidic refluxes as determinants of heartburn perception in gastroesophageal reflux disease patients with normal esophageal acid exposure 103
Dynamics of persistent TT virus infection, as estimated in patients treated with alpha interferon for concomitant hepatitis C 102
Serum pepsinogen I and gastrin-17 levels are predictable of atrophic gastritis in patients with autoimmune thyroiditis and anti-gastric parietal cell autoantibodies. 102
Assessment of bowel wall inflammation in Crohn's disease by a new quantitative ultrasound analysis as compared to vascularization in healthy volunteers bowel wall. 102
Le risque d'adenocarcinome sur oesophage de Barrett: resultat d'une etude multicentrique 101
Blood levels of TT virus following immune stimulation with influenza or hepatitis B vaccine 101
Esophageal baseline impedance levels in patients with pathophysiological characteristics of functional heartburn. 101
Alcune considerazioni sull'approccio psico-medico-sociale ai problemi alcol-correlati XI Congresso S.I.A. 100
Impairment of chemical clearance and mucosal integrity distinguishes hypersensitive esophagus from functional heartburn 100
Assessment of proliferating cell nuclear antigen expression in dysplastic intestinal type Barrett's esophagus 98
Pelvic floor dyssynergia and psychiatric disorders. Does the snake bite its tail? 98
Gastrointestinal manifestations in myotonic muscular dystrophy 98
Alginate controls heartburn in patients with erosive and nonerosive reflux disease 98
Totale 12.227
Categoria #
all - tutte 78.332
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 78.332


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204.595 0 0 1.234 273 477 504 470 291 489 304 461 92
2020/20212.771 253 93 243 199 321 154 249 217 191 217 148 486
2021/20223.441 41 254 58 253 642 466 71 180 163 77 135 1.101
2022/20234.111 495 497 259 369 533 612 43 328 630 19 268 58
2023/20243.599 596 429 602 241 452 639 73 75 60 38 80 314
2024/2025483 51 408 24 0 0 0 0 0 0 0 0 0
Totale 30.183